Economic impact of sevelamer in patients with ESRD [4]

Kidney International

Volumn 67, Issue 4, 2005, Pages 1636-1637

  Qunibi, Wajeh Y ^a,b   Nolan, Charles R ^a  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ACETATE; SEVELAMER;

DRUG EFFICACY; ECONOMIC ASPECT; HOSPITALIZATION; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; LETTER; PRIORITY JOURNAL;

EID: 16244418673     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.247_6.x     Document Type: Letter

References (4)

1. MANNS B, STEVENS L, MISKULIN D, et al: A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int 66:1239-1247, 2004
2. QUNIBI WY, HOOTKINS RE, MCDOWEL LL, et al: Treatment of hyperphosphatemia in hemodialysis patients: The calcium acetate renagel evaluation (CARE study). Kidney Int 65:1914-1926, 2004
3. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl 3):S1-S202, 2003
4. QUNIBI WY: Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD). Kidney Int 66(Suppl 90):S8-S12, 2004